Andere Sprachen Medicure Inc.

Aktien

A1J7TZ

CA58469E4085

MPH

Verzögert Toronto S.E. Andere Börsenplätze 17:32:40 21.06.2024			% 5 Tage	% 1. Jan.
1,02 ^CAD	-6,42 %		-6,42 %	-27,14 %

29.05.	Transcript : Medicure Inc., Q1 2024 Earnings Call, May 29, 2024
28.05.	Medicure Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Medicure : Q1 - March 31, 2024	28.05.
MEDICURE : REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2024 AND ANNUAL GENERAL MEETING DIRECTOR ELECTION RESULTS	28.05.
Medicure Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	28.05.
Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as Director	28.05.
MEDICURE RECEIVES US FDA FAST TRACK DESIGNATION FOR MC-1 FOR PNPO DEFICIENCY	24.04.
Medicure: Q4 Earnings Snapshot	08.04.
Medicure Swung to a Loss in 2023 on Lower Sales	08.04.
Medicure Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08.04.
MEDICURE TO PRESENT FINANCIAL RESULTS ON APRIL 9, 2024 CALL at 8:30 AM ET FOR QUARTER AND YEAR ENDED DECEMBER 31, 2023	05.04.
MEDICURE ANNOUNCES NEW PARTNERSHIP THROUGH ITS MARLEY DRUG SUBSIDIARY TO PROVIDE BRENZAVVY AS AN AFFORDABLE MEDICATION FOR AMERICANS WITH TYPE 2 DIABETES	06.12.
Marley Drug Announces A Partnership with TheracosBio to Distribute A Newly Approved Diabetes Drug, BRENZAVVY	06.12.
MEDICURE ANNOUNCES FDA PROVIDES COMPLETE APPROVAL TO ENROLL PATIENTS IN ITS PIVOTAL PHASE 3 TRIAL FOR TREATMENT OF RARE PEDIATRIC DISEASE	24.11.
Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease	23.11.
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2023	22.11.
Medicure: Q3 Earnings Snapshot	21.11.
Medicure Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21.11.
MEDICURE REITERATES ITS COMMITMENT TO PROVIDING EXCEPTIONAL ACCESS TO ITS BRANDED PITAVASTATIN TO PEOPLE LIVING WITH HIV	30.08.23
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2023	31.07.23
Medicure Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29.07.23
Medicure : Q2 - June 30, 2023	28.07.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Medicure Inc.

Aktien

A1J7TZ

CA58469E4085

MPH

Andere Sprachen

Filter